ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.
Abstract
Chromosomal rearrangements involving erythroblast transformation specific (ETS) family transcription factors were recently defined as the most common genetic alterations in human prostate cancer. Despite their prevalence, it is unclear what quantitative role they play in either initiation or progression of the disease. Using a lentiviral transduction and dissociated cell prostate regeneration approach, we find that acutely increased expression of ETS proteins in adult murine prostate epithelial cells is sufficient to induce the formation of epithelial hyperplasia and focal prostatic intraepithelial neoplasia (PIN) lesions, but not progression to carcinoma. However, combined expression of ERG with additional genetic alternations associated with human prostate cancer can lead to aggressive disease. Although ERG overexpression does not cooperate with loss of the tumor suppressor p53, it does collaborate with alterations in PI3K signaling, such as Pten knockdown or AKT up-regulation, to produce a well-differentiated adenocarcinoma. Most striking is our finding that overexpression of androgen receptor (AR) does not give rise to any hyperplastic lesions, but when combined with high levels of ERG, it promotes the development of a more poorly differentiated, invasive adenocarcinoma. These findings suggest that in human prostate cancer, the most potent function of ETS gene fusions may be to synergize with alternative genetic events and provide different pathways for carcinoma production and invasive behavior. Our results provide direct evidence for selective cooperating events in ERG-induced prostate tumorigenesis and offer a rational basis for combined therapeutic interventions against multiple oncogenic pathways in prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, the genetic finding that ETS and AR genes cooperate in oncogenesis (175) indicates that this mechanism is more complex than our current understanding and may differ on a target-by-target basis (180).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [175]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 2×
“But the cells must accumulate several other rate-limiting mutations over a long period to become malignant (2).”
BackgroundResultRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 2×
“AR is commonly mutated or amplified in human PCa (3, 35), and the AR pathway is the most extensively studied pathway in PCa because of its role in late-stage hormone-refractory PCa.”
BackgroundCrucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993 · cited 1×
“p53 deletion has been shown to synergize with Pten targeted inactivation (26) or Rb deficiency (27) to induce murine PCa, indicating that loss of p53 may play an important role in initiation and progression of PCa.”
BackgroundThe multistep nature of cancer
Vogelstein, B., & Kinzler, K. W. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90209-z · Cited by 1,853 · cited 1×
“H cancer is a multigene disorder in which several somatic mutations in cancer predisposition genes are required in a stepwise manner (1).”
BackgroundPurification and unique properties of mammary epithelial stem cells
Stingl, J., Eirew, P., Ricketson, I., Shackleton, M., Vaillant, F., Choi, D., Li, H. I., & Eaves, C. J. (2006) · Nature · doi:10.1038/nature04496 · Cited by 1,559 · cited 1×
“Previous studies in our lab showed that CD49f (integrin 6), a stem cell marker in multiple epithelial tissues (21, 22), was predominantly expressed on the basal surface of prostate basal cells and colocalized with its extracellular matrix ligand, laminin (22).”
BackgroundOncogenic Transcription Factors in the Human Acute Leukemias
Look, A. T. (1997) · Science · doi:10.1126/science.278.5340.1059 · Cited by 1,187
Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134 · cited 2×
“With the promising progress in the development of PI3K inhibitors such as SF1126 and NVP-BEZ235 (42, 43) and more potent antiandrogen agents (44), strategies to specifically inhibit ETS transcription factors may be the critical component for combined target therapy in the treatment for ETS overexpressing PCa.”
BackgroundWang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109 · cited 1×
“Although activation of AKT in human PCa typically occurs through loss of PTEN, the activated AKT and Pten-deficient PCa mouse models demonstrate different degrees of disease progression, because constitutively active AKT only results in PIN lesion, whereas Pten deletion leads to metastatic PCa (32, 33).”
BackgroundDistinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., Cao, Q., Han, B., et al. (2007) · Nature · doi:10.1038/nature06024 · Cited by 844 · cited 2×
“1B), characterized by focal hypercellularity and increased epithelial tufting, which is consistent with the observations in ETV1 transgenic mice (8).”
BackgroundResultMolecular genetics of prostate cancer
Abate-Shen, C., & Shen, M. M. (2000) · Genes & Development · doi:10.1101/gad.819500 · Cited by 735
Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer
Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., Cao, Q., Prensner, J. R., Rubin, M. A., Shah, R. B., et al. (2008) · Neoplasia · doi:10.1593/neo.07822 · Cited by 690 · cited 1×
“Chinnaiyan and co-workers (16) reported similar observations by using the same strategy on the FVB background.”
Recurrent gene fusions in prostate cancer
Kumar-Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2402 · Cited by 664 · cited 4×
“Given that up-regulation of ETS transcription factors is mainly driven by the androgenresponsive TMPRSS2 promoter in most samples of human PCa (6, 11), it is reasonable to hypothesize that both ETS overexpression and AR signaling coexist in malignant prostate epithelial cells.”
BackgroundInfluentialTMPRSS2:ERG Fusion-Associated Deletions Provide Insight into the Heterogeneity of Prostate Cancer
Perner, S., Demichelis, F., Beroukhim, R., Schmidt, F. H., Mosquera, J.-M., Setlur, S., Tchinda, J., Tomlins, S. A., Hofer, M. D., Pienta, K. G., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1482 · Cited by 502 · cited 1×
“This fusion results in overexpression of full-length or truncated ERG protein in prostate epithelial cells and was found to be associated with an aggressive phenotype of PCa (11, 12).”
BackgroundCooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis
King, J. C., Xu, J., Wongvipat, J., Hieronymus, H., Carver, B. S., Leung, D. H., Taylor, B. S., Sander, C., Cardiff, R. D., Couto, S. S., et al. (2009) · Nature Genetics · doi:10.1038/ng.371 · Cited by 477 · cited 1×
“However, Pandolfi and co-workers (17) and Sawyers and co-workers (18) described that their ERG transgenic mice (on the C57BL/6 or FVB background, respectively) possess little observable pathological findings with no increase in cell proliferation.”
BackgroundPathological and molecular aspects of prostate cancer
DeMarzo, A. M., Nelson, W. G., Isaacs, W. B., & Epstein, J. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12779-1 · Cited by 472
TMPRSS2:ETV4 Gene Fusions Define a Third Molecular Subtype of Prostate Cancer
Tomlins, S. A., Mehra, R., Rhodes, D. R., Smith, L. R., Roulston, D., Helgeson, B. E., Cao, X., Wei, J. T., Rubin, M. A., Shah, R. B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0168 · Cited by 469
Xin, L., Lawson, D. A., & Witte, O. N. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502320102 · Cited by 423
Self-citationIsolation and functional characterization of murine prostate stem cells
Lawson, D. A., Xin, L., Lukacs, R. U., Cheng, D., & Witte, O. N. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609684104 · Cited by 399
Self-citationWu, X., Wu, J., Huang, J., Powell, W. C., Zhang, J., Matusik, R. J., Sangiorgi, F. O., Maxson, R. E., Sucov, H. M., & Roy-Burman, P. (2001) · Mechanisms of Development · doi:10.1016/s0925-4773(00)00551-7 · Cited by 390 · cited 1×
“Nelson and Vasioukhin and co-workers (13) generated a mouse strain with prostate-specific expression of the truncated ERG protein under the control of the modified probasin (ARR2PB) promoter, which displays significant prepubertal transcriptional activity (14, 15).”
BackgroundTargeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 389 · cited 1×
“With the promising progress in the development of PI3K inhibitors such as SF1126 and NVP-BEZ235 (42, 43) and more potent antiandrogen agents (44), strategies to specifically inhibit ETS transcription factors may be the critical component for combined target therapy in the treatment for ETS overexpressing PCa.”
BackgroundSynergy of p53 and Rb Deficiency in a Conditional Mouse Model for Metastatic Prostate Cancer
Zhou, Z., Flesken-Nikitin, A., Corney, D. C., Wang, W., Goodrich, D. W., Roy-Burman, P., & Nikitin, A. Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0486 · Cited by 316 · cited 1×
“p53 deletion has been shown to synergize with Pten targeted inactivation (26) or Rb deficiency (27) to induce murine PCa, indicating that loss of p53 may play an important role in initiation and progression of PCa.”
BackgroundA causal role for ERG in neoplastic transformation of prostate epithelium
Klezovitch, O., Risk, M., Coleman, I., Lucas, J. M., Null, M., True, L. D., Nelson, P. S., & Vasioukhin, V. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711711105 · Cited by 302 · cited 2×
“(13) reported that in addition to the decreased ratio of basal cells to the total prostate epithelial cells, the expression levels of CD104 (integrin 4), a binding partner of CD49f to form a lamininbinding integrin receptor, were elevated in some luminal prostate cells from ERG transgenic mice.”
BackgroundProstate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model
Majumder, P. K., Yeh, J. J., George, D. J., Febbo, P. G., Kum, J., Xue, Q., Bikoff, R., Ma, H., Kantoff, P. W., Golub, T. R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1232229100 · Cited by 285 · cited 1×
“Although activation of AKT in human PCa typically occurs through loss of PTEN, the activated AKT and Pten-deficient PCa mouse models demonstrate different degrees of disease progression, because constitutively active AKT only results in PIN lesion, whereas Pten deletion leads to metastatic PCa (32, 33).”
BackgroundGarlich, J. R., De, P., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 279 · cited 2×
“With the promising progress in the development of PI3K inhibitors such as SF1126 and NVP-BEZ235 (42, 43) and more potent antiandrogen agents (44), strategies to specifically inhibit ETS transcription factors may be the critical component for combined target therapy in the treatment for ETS overexpressing PCa.”
BackgroundCharacterization of TMPRSS2:ETV5 and SLC45A3:ETV5 Gene Fusions in Prostate Cancer
Helgeson, B. E., Tomlins, S. A., Shah, N., Laxman, B., Cao, Q., Prensner, J. R., Cao, X., Singla, N., Montie, J. E., Varambally, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5352 · Cited by 276
Sun, C., Dobi, A., Mohamed, A., Li, H., Thangapazham, R. L., Furusato, B., Shaheduzzaman, S., Tan, S.-H., Vaidyanathan, G., Whitman, E., et al. (2008) · Oncogene · doi:10.1038/onc.2008.183 · Cited by 253 · cited 1×
“demonstrated that c-MYC is down-regulated after siRNA-mediated knockdown of ERG in VCaP cells, a human PCa cell line that harbors the TMPRSS2-ERG fusion (23).”
BackgroundHermans, K. G., van Marion, R., van Dekken, H., Jenster, G., van Weerden, W. M., & Trapman, J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1871 · Cited by 240 · cited 1×
“The TMPRSS2-ERG fusion at chromosome 21q22, via either interstitial deletion or chromosomal translocation, is the most predominant subtype (10, 11).”
BackgroundZhang, J., Thomas, T. Z., Kasper, S., & Matusik, R. J. (2000) · Endocrinology · doi:10.1210/endo.141.12.7837 · Cited by 219 · cited 1×
“Nelson and Vasioukhin and co-workers (13) generated a mouse strain with prostate-specific expression of the truncated ERG protein under the control of the modified probasin (ARR2PB) promoter, which displays significant prepubertal transcriptional activity (14, 15).”
BackgroundMemarzadeh, S., Xin, L., Mulholland, D. J., Mansukhani, A., Wu, H., Teitell, M. A., & Witte, O. N. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.002 · Cited by 201 · cited 2×
“Mouse anti-GFP monoclonal antibody clone 3C2-G2 was produced in Owen Witte’s lab (45).”
MethodSelf-citationXin, L., Ide, H., Kim, Y., Dubey, P., & Witte, O. N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1734139100 · Cited by 195
Self-citationMutation of the androgen receptor causes oncogenic transformation of the prostate.
Han, G., Buchanan, G., Ittmann, M., Harris, J. M., Yu, X., DeMayo, F. J., Tilley, W., & Greenberg, N. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408925102 · Cited by 192 · cited 1×
“Although it is well known that increased AR signaling is associated with PCa progression, transgenic mice with prostatespecific overexpression of wild-type AR did not display any abnormal phenotype (40).”
BackgroundYoshimoto, M., Cutz, J.-C., Nuin, P. A. S., Joshua, A. M., Bayani, J., Evans, A. J., Zielenska, M., & Squire, J. A. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.04.003 · Cited by 181 · cited 5×
“These pathological manifestations of ERG-transduced prostate glands resemble the morphological features of signet ring cells that were found in a subset of human PCas harboring the TMPRSS2-ERG gene fusion (20).”
BackgroundInfluentialGao, J., Arnold, J. T., & Isaacs, J. T. (2001) · PubMed · Cited by 175
Xin, L., Teitell, M. A., Lawson, D. A., Kwon, A., Mellinghoff, I. K., & Witte, O. N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602567103 · Cited by 158 · cited 2×
“Consistent with the previous findings (31), forced expression of AR single gene impaired the regenerative capacity of the dissociated murine prostate cells, resulting in fewer prostate tubules in AR-transduced prostate grafts (Fig.”
BackgroundResultSelf-citationMorphological features of TMPRSS2–ERG gene fusion prostate cancer
Mosquera, J. M., Perner, S., Demichelis, F., Kim, R., Hofer, M. D., Mertz, K. D., Paris, P., Simko, J., Collins, C. C., Bismar, T., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2154 · Cited by 144 · cited 1×
“These pathological manifestations of ERG-transduced prostate glands resemble the morphological features of signet ring cells that were found in a subset of human PCas harboring the TMPRSS2-ERG gene fusion (20).”
BackgroundETS rearrangements and prostate cancer initiation
Carver, B. S., Tran, J., Chen, Z., Carracedo-Perez, A., Alimonti, A., Nardella, C., Gopalan, A., Scardino, P. T., Cordon-Cardo, C., Gerald, W., et al. (2009) · Nature · doi:10.1038/nature07738 · Cited by 111
Pereira, D. S., Dorrell, C., Ito, C. Y., Gan, O. I., Murdoch, B., Rao, V. N., Zou, J.-P., Reddy, E. S. P., & Dick, J. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8239 · Cited by 77 · cited 1×
“However, similar to the intermediate preleukemia state of ERG-transduced hematopoietic cells (39), the introduction of ERG single gene is not sufficient to cause full transformation of prostate epithelial cells.”
BackgroundPleiotropic functional properties of androgen receptor mutants in prostate cancer
Bergerat, J.-P., & Céraline, J. (2009) · Human Mutation · doi:10.1002/humu.20848 · Cited by 75 · cited 1×
“It has been proposed that in addition to an autocrine mechanism (37), AR signaling in PCa cells can act on neighboring malignant cells in a paracrine manner (38).”
BackgroundAlterations of p53 are common in early stage prostate cancer.
Downing, Russell, P. J., & Jackson, P. (2003) · PubMed · Cited by 67
Verger, A., Buisine, E., Carrère, S., Wintjens, R., Flourens, A., Coll, J., Stéhelin, D., & Duterque-Coquillaud, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010208200 · Cited by 50 · cited 2×
“Moreover, we found that the expression levels of c-Jun protein, a known ERG-binding partner (24), were significantly increased in the epithelial cells of ERG-transduced glands compared with adjacent normal glands (Fig.”
BackgroundCai, C., Hsieh, C.-L., & Shemshedini, L. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0430 · Cited by 39 · cited 1×
“This interaction could be mediated by c-Jun, which has been shown to bind to both ERG (24) and AR (41) and found to be up-regulated in ERG expressing regenerated glands.”
BackgroundEvidence of recurrent gene fusions in common epithelial tumors
Kumar‐Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.09.005 · Cited by 34 · cited 1×
“Several lines of evidence in epithelial cancers of distinct tissue origins suggest that acquired chromosomal rearrangements could also be the common genetic events in many, if not all, epithelial cancers (5).”
BackgroundShaffer, D. R., & Pandolfi, P. P. (2006) · Nature Medicine · doi:10.1038/nm0106-14 · Cited by 23 · cited 3×
“However, Pandolfi and co-workers (17) and Sawyers and co-workers (18) described that their ERG transgenic mice (on the C57BL/6 or FVB background, respectively) possess little observable pathological findings with no increase in cell proliferation.”
ResultPortella, G., Borselli, C., Santoro, M. M., Gerbasio, D., D'Armiento, M. R., Dumont, J. E., Ledent, C. A., Rothstein, J. L., Vecchio, G., & Fusco, A. (2001) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504001108747800 · Cited by 3 · cited 1×
“We found no evidence to support cooperation between loss of p53 and increased expression of ERG in our 8-week assay, suggesting that 2 oncogenic influences do not always collaborate to advance the disease (28).”
Background
Cited by
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
“ERG in transgenic mice and in a prostate tissue reconstitution model (Carver et al., 2009; King et al., 2009; Zong et al., 2009).”
BackgroundMolecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
“Furthermore , this overall approach can been greatly extended by efficient lentiviral infection of dissociated prostate epithelial cells, followed by tissue recombination, allowing for overexpression and knockdown approaches for analysis of gene function (Xin et al. 2003, 2006; Zong et al. 2009).”
BackgroundYu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
“…of a CMV-promoter driven AR (thus not susceptible to ERG repression, mimicking a hormone-refractory state with AR amplification), together with forced ERG overexpression, has recently been shown to promote the development of a more poorly differentiated, invasive adenocarcinoma (Zong et al., 2009).”
BackgroundIdentification of a Cell of Origin for Human Prostate Cancer
Goldstein, A. S., Huang, J., Guo, C., Garraway, I. P., & Witte, O. N. (2010) · Science · doi:10.1126/science.1189992 · Cited by 554
Self-citationGenomic and biochemical insights into the specificity of ETS transcription factors
Hollenhorst, P. C., McIntosh, L. P., & Graves, B. J. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.79.081507.103945 · Cited by 490
“However, the genetic finding that ETS and AR genes cooperate in oncogenesis (175) indicates that this mechanism is more complex than our current understanding and may differ on a target-by-target basis (180).”
Metadata
- Authors
- Zong, Y., Xin, L., Goldstein, A. S., Lawson, D. A., Teitell, M. A., & Witte, O. N.
- Affiliations
- Howard Hughes Medical Institute (US)
- Department of Microbiology, Immunology, and Molecular Genetics,
- Molecular Biology Institute,
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-07-28
- Volume
- 106
- Issue
- 30
- Pages
- 12465-12470
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2708977
- OpenAlex
- W1963749564
- Cited by
- 203
- References
- 46
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 11 · 2018: 7 · 2017: 12 · 2016: 11 · 2015: 13 · 2014: 22 · 2013: 35 · 2012: 21
- FWCI
- 19.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Prostate Cancer Foundation
- Leukemia and Lymphoma Society
- National Cancer Institute (R00CA125937)
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- ETS transcription factors, ERG, prostate cancer, prostate tumorigenesis, prostatic intraepithelial neoplasia, epithelial hyperplasia, PI3K signaling, PTEN loss, Akt, androgen receptor, p53, tumor suppressor loss, adenocarcinoma differentiation, invasive carcinoma
- MeSH terms
- Transcriptional Regulator ERG, Red Fluorescent Protein, Animals, Cell Transformation, Neoplastic, Cells, Cultured, DNA-Binding Proteins, Epithelial Cells, Hyperplasia, Immunohistochemistry, Luminescent Proteins, Male, Mice, Inbred C57BL, Mutation, Prostate, Prostatic Neoplasms, Transcription Factors, Blotting, Western, Signal Transduction, Oncogene Proteins, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-myc, Proto-Oncogene Proteins c-jun, Prostatic Intraepithelial Neoplasia, Phosphatidylinositol 3-Kinases, Integrin alpha6, Proto-Oncogene Proteins c-ets, Mice, Keratin-5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.